Abstract: Objective To compare the efficacy and safety of domestic and imported recombinant human follicle stimulating hormone (rFSH) preparation for ovulation induction in non-low-response population with long-acting program in follicular phase. Methods Non-ovarian infertility patients with low response were retrospectively enrolled in our center for the first time to receive long-acting follicular phase IVF/ICSI assisted fertility treatment, all of whom received a COS longacting follicular phase therapy, and were divided into the domestic rFSH group (n=267) and the imported rFSH group (n= 240) according to different use of rFSH. Ovarian response, medication, egg fertilization and embryo, fresh embryo transfer and embryo thawing transfer were compared between the two groups. Results During the process of superovulation, the level of E 2 on HCG day was lower in the domestic rFSH group than that in the imported rFSH group (P＜0.05). There were no significant differences in total Gn, days of Gn use, the number of MⅡ eggs, the number of D3 excellent embryos and number of high-quality blastocysts between the two groups (P＞0.05). In the primary efficacy indicators, there were no significant differences in the average number of egg retrieved, cumulative live birth rate of one COS number of fresh embryos, the clinical pregnancy rate in the transplantation cycle, and the clinical pregnancy rate in the freeze-thaw transplantation cycle between the two groups (P＞0.05). Conclusion Compared with imported rFSH in the follicular phase, domestic rFSH can achieve the same safe efficacy and clinical outcome in non-low response patients.

Key words: follicle stimulating hormone, human, fertilization in vitro, embryo transfer, non-low response population, long-acting program for follicular phase, clinical pregnancy rate, live birth rate